publication venue for
- Chronic myeloid leukemia: Is it dusk or dawn?. 29. 2016
- Learning from Waldenstrom Macroglobulinemia.. 29. 2016
- Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults. 2023
- Clonal Hematopoiesis and risk of Acute Myeloid Leukemia. 2019
- Clonal Hematopoiesis and therapy related MDS/AML. 2019
- Improving outcomes in primary CNS lymphoma. 2018
- Peripheral T-cell lymphoma - are we making progress? 2018
- Optimal management of the young patient CLL patient. 2017
- How important is NK alloreactivity and KIR in allogeneic transplantation? 2016
- Management of CML-blast crisis. 2016
- Future therapeutic options for patients with Waldenström macroglobulinemia. 2016
- Monoclonal gammopathy of undetermined significance and Waldenström's macroglobulinemia. 2016
- Role of intestinal microbiota in transplantation outcomes. 2015
- Hairy cell leukemia: Past, present and future. 2015
- IDH2 inhibition in AML: Finally progress? 2015
- Transplant for MDS: challenges and emerging strategies. 2014
- The new thrombopoietic agenda: impact on leukemias and MDS. 2014
- A primer on genomic and epigenomic alterations in the myeloproliferative neoplasms. 2014
- Molecular pathogenesis of AML: translating insights to the clinic. 2013
- Management of mantle cell lymphoma in the elderly. 2012
- Novel strategies for adoptive therapy following HLA disparate transplants. 2011
- Greater than the sum of their parts: combination strategies for immune regeneration following allogeneic hematopoietic stem cell transplantation. 2011
- Epigenetics in AML. 2010
- Mechanisms of mutations in myeloproliferative neoplasms. 2009
- Management of drug toxicities in chronic myeloid leukaemia. 2009
- The blast phase of chronic myeloid leukaemia. 2009
- The coagulopathy of acute promyelocytic leukaemia revisited. 2009
- Peptide vaccines for myeloid leukaemias. 2008
- Modern histological classification of low grade B-cell lymphomas. 2005
- Biology of plasma cells. 2005
- Globin gene transfer for treatment of the beta-thalassemias and sickle cell disease. 2004
- First-generation agents: aspirin, heparin and coumarins. 2004
- Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. 2003